All News
New Advances in Ultrasound Diagnostics for Psoriatic Arthritis
ACR Press Release
Two pivotal studies led by an international team of rheumatology experts will be presented at ACR Convergence 2025, showcasing major strides in the ultrasound-based diagnosis of enthesitis in psoriatic arthritis (PsA).
Read Article
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
Read Article
In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week 16. Proteomic profiling identified 133 unique proteins in males and 177 in females vs sex-matched healthy controls. Females showed greater enrichment in https://t.co/TTAWUtOLP0
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Abstract 0874:
At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures
🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses
🔹 Greater ↓in PASDAS and mCPDAI
🔹 Benefits seen in both men and women
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Sex based differences in PsA proteomics
Analyse from POETYK PSA 1 & 2 deucravacitinib RCT
Large overlap but female pts specificities, Upregulation of:
-JAK STAT pathway
-Cytokine interaction
Linked with higher disease activity in female groups
Yes Correlation, but not https://t.co/VwiVOkxpoB
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs
After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs
Interesting data, More research reqd
#ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O
Links:
sheila RHEUMarampa ( View Tweet)
TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls
Without much surprise GLP-1 treated pts had lower risk of MACE and death
Observational, retrospective study.
Now awaiting the prospective evidence.
RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK
Aurelie Najm AurelieRheumo ( View Tweet)
What is better in #PsA post #TNFi?
#RCT of #secukinumab v #ustekinumab
The big 🤔? #IL17Ai vs IL12/23i
🏆 #Cosentyx
✈️✅PASI
⚜️✅ACR50
Will H2H studies change our #prescribing?🤷♀️
#rheums Rx #IL17i>#IL12i/23i vs #derms
#ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H
Janet Pope Janetbirdope ( View Tweet)
To #cycle within or go to another drug class I #axSpA?
#RCT of #TNFi-IR
👇
2nd #TNFi v #IL17i
#IJDM it doesn’t matter what choice as
#IL17i WAS NOT superior to TNFi cycling from 1st -2nd
👍 stay in #TNFi class = change to #IL17i
#ACR25 @RheumNow abst#LB09
#ACRBest @ACRheum https://t.co/VCdL5CUYUa
Links:
Janet Pope Janetbirdope ( View Tweet)
The CLASSIC study validated the performance of the 2009 ASAS classification criteria
Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90%
🔸Pso was included
🔸⬆️CRP replaced dactylitis
#ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa
Links:
sheila RHEUMarampa ( View Tweet)
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Time for the 2nd plenary session! 🎤
#0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients.
Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP
Mrinalini Dey DrMiniDey ( View Tweet)
This morning in the plenary, same theme, but in PsA:
Similar metabolic/CV concerns
Similarly benefit from GLP-1 RA
looking at TriNetX data again, reduced MACE
Now prospective trials in rheum disease, for both metabolic benefits & disease activity?
#ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG
David Liew drdavidliew ( View Tweet)
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
High prevalence of sleep related symptoms in PsA pts!
-Snoring 53%
-Morning fatigue 68%
-Obstructive Sleep Apnea in 50%
14% mild 19% moderate 17% severe
Estimated prevalence 36%
No correlation between OSA and PsA disease activity or comorbidities
But small cohort! https://t.co/VKe7qcHIRm
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. Ogdie on emerging PsA tx:
“It’s not just about the pharmacotherapy but also about making the patient feel better”
Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on.
#ACR25 @RheumNow https://t.co/FN3EEowkDP
Links:
sheila RHEUMarampa ( View Tweet)
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
Links:
sheila RHEUMarampa ( View Tweet)
What are the RFs for progression of Pso to PsA?
🔸PsO disease severity - 3.2x risk —>PsA
🔸Phenotype - nail involvement
🔸Obesity - 6x higher risk of developing PsA
🔸MSK symptoms - arthralgia & heel pain
#ACR25 @RheumNow https://t.co/UPXuxBPyKI
Links:
sheila RHEUMarampa ( View Tweet)
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Trying to reach RA, PsA patients on social media, to participate in studies?
Simple, informational messages work for recruitment
Message framing affects engagement but not recruitment
The more we understand, the better we can reach the right people
#ACR25 ABST0187 @RheumNow https://t.co/JoAthXhXvi
David Liew drdavidliew ( View Tweet)
